[Skip to Content]
[Skip to Content Landing]
April 18, 1986

DTP Vaccine

Author Affiliations

University of Colorado Health Sciences Center Denver
Connaught Laboratories Inc Swiftwater, Pa

JAMA. 1986;255(15):2026. doi:10.1001/jama.1986.03370150068023

To the Editor.—  In their latest recommendations regarding the diphtheria and tetanus toxoids and pertussis (DTP) vaccines, the Centers for Disease Control provide an excellent review.1 The DTP vaccine has been the subject of widespread controversy. Recent prospective data have shown a high incidence of immediate adverse reactions and long-term sequelae temporally associated with the vaccine.1,2 This has resulted in some parents requesting that the pertussis component be omitted from routine immunization.In response to the growing concern about the acceptability of DTP vaccine, we conducted a study to investigate the validity of reduced-dose immunizations with DTP vaccine.3 Many clinicians have empirically adopted this approach in response to parental anxiety.The study demonstrated that a reduced-dose series of three primary immunizations and a booster with DTP vaccine provided equivalent antibody response, while significantly reducing the incidence and severity of adverse reactions. Febrile and local reactions were reduced